BAY1902607 + itraconazole

**BAY1902607 + itraconazole** is a combination of two agents: BAY1902607 (also known as filapixant), a novel selective antagonist of the P2X3 receptor being developed for the treatment of refractory or unexplained chronic cough and conditions such as endometriosis; and itraconazole, a triazole antifungal widely approved and marketed for the treatment of superficial and systemic fungal infections. - **BAY1902607 (filapixant)** acts by selectively inhibiting the P2X3 receptor, a ligand-gated ion channel involved in sensory neuronal signaling, most notably implicated in the cough reflex[2][4][9][6]. It reduces cough frequency and severity in patients with refractory chronic cough, with a side-effect profile notable for dose-dependent taste disturbances[4][6]. - **Itraconazole** is a small-molecule antifungal that inhibits fungal cytochrome P450 14α-demethylase, impairing ergosterol synthesis and disrupting fungal cell membrane formation[7][10]. It is also a strong inhibitor of human CYP3A4 enzyme and drug transporters such as P-glycoprotein and BCRP, resulting in frequent and potentially significant drug-drug interactions[5][7]. - No combination product named "BAY1902607 + itraconazole" is approved or regularly used; co-administration may be under investigation due to itraconazole's known ability to inhibit CYP3A4 and increase exposure of certain drugs, potentially including BAY1902607.

Other names

filapixantITZ